Fundz

Proteon Therapeutics Inc reported raising $22 Million in an initial SEC Form D filing, from an offering of $22 Million

PUBLIC · TARAAug 16, 2017

Amount Raised

$22 Million

$22 Million sold, per SEC Form D (first sale Aug 16, 2017)

Round Type

Venture

New YorkBiotechnologyHealth CareTherapeutics

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Protara Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Pulse Biosciences, Inc. raised $30M on September 28, 2017.
  • Alcresta Therapeutics raised $10M on September 25, 2017.
  • Theriva Biologics raised $12M on September 13, 2017.
  • Azora Therapeutics, Inc. (DE) raised $40K on August 31, 2017.
  • DTx Pharma, Inc. raised $25K (Pre-Seed) on August 30, 2017.
  • VistaGen raised $1M on August 22, 2017.

Who to call at Protara Therapeutics, and when

A new round usually means Protara Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Protara Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Protara Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Protara Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Protara Therapeutics

Location

New York, New York, United States

About

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Protara Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsShane W., Chief People Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Protara Therapeutics's next move

See what Strategic adds

Protara Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.